HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
Share
Why It Matters
An expert analyst says Journey Medical is worth buying and stays worth $13 per share. This means the analyst thinks the company is doing well and should keep growing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.